TrialThe Journal of clinical endocrinology and metabolism2022

Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2.

Christoph Nowak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.